Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study

This article has no abstract
Epistemonikos ID: 6ec1f2b1e9fc80e05de7674e1330c7c9544bd812
First added on: Feb 08, 2025